Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CTX001 in Healthy Adults
NCT07577817Phase 1Recruiting
- Sponsor
- Cajal Therapeutics
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Modality
- Gene Silencing, CRISPR-Cas9, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of exagamglogene autotemcel in anemia, iron deficiency anemia (IDA) and chronic kidney disease (CKD) (6 arms), sponsored by Cajal Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 15 days, Serious Treatment-Emergent Adverse Events at 15 days and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
exagamglogene autotemcel
03
Conditions
anemiairon deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07577817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577817.